- 1 Title: Impact of COVID-19 and Effects of Vaccination with BNT162b2 on Patient-Reported
- 2 Health-Related Quality of Life, Symptoms, and Work Productivity Among US Adult Outpatients
- 3 with SARS-CoV-2

7

14

20

21

22

- 5 **Authors:** Manuela Di Fusco^{1*}, Xiaowu Sun², Mary M. Moran³, Henriette Coetzer², Joann M.
- 6 Zamparo³, Laura Puzniak³, Mary B. Alvarez⁴, Ying P. Tabak², Joseph C. Cappelleri⁵
- **8** Affiliations:
- 9 ¹ Pfizer Inc., Health Economics and Outcomes Research, New York, NY, USA
- 10 ² CVS Health, Woonsocket, RI, USA
- 11 ³ Pfizer Inc., MDSCA Vaccines, Collegeville, PA, USA
- ⁴ Pfizer Inc., Field Medical Outcomes and Analytics, New York, NY, USA
- 13 ⁵ Pfizer Inc., Statistical Research and Data Science Center, Groton, CT, USA
- 15 *Corresponding author:
- 16 Manuela Di Fusco
- 17 Health Economics and Outcomes Research
- 18 Pfizer, Inc., New York, NY, USA
- 19 Manuela.difusco@pfizer.com

ABSTRACT

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Background: Although there is extensive literature on the clinical benefits of COVID-19 vaccination, data on humanistic effects are limited. This study evaluated the impact of SARS-CoV-2 infection on symptoms, Health Related Quality of Life (HRQoL) and Work Productivity and Impairment (WPAI) prior to and one month following infection, and compared results between individuals vaccinated with BNT162b2 and those unvaccinated. **Methods:** Subjects with ≥1 self-reported symptom and positive RT-PCR for SARS-CoV-2 at CVS Health US test sites were recruited between 01/31/2022-04/30/2022. Socio-demographics, clinical characteristics and vaccination status were evaluated. Self-reported symptoms, HRQoL, and WPAI outcomes were assessed using questionnaires and validated instruments (EQ-5D-5L, WPAI-GH) across acute COVID time points from pre-COVID to Week 4, and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for several covariates. Effect size (ES) of Cohen's d was calculated to quantify the magnitude of outcome changes within and between vaccination groups. **Results:** The study population included 430 subjects: 197 unvaccinated and 233 vaccinated with BNT162b2. Mean (SD) age was 42.4 years (14.3), 76.0% were female, 38.8% reported prior infection and 24.2% at least one comorbidity. Statistically significant differences in outcomes were observed compared with baseline and between groups. The EQ-Visual analogue scale scores and Utility Index dropped in both cohorts at Day 3 and increased by Week 4, but did not return to pre-COVID levels. The mean changes were statistically lower in the BNT162b2 cohort at Day 3 and Week 4. The BNT162b2 cohort reported lower prevalence and fewer symptoms at index date and Week 4. At Week 1, COVID-19 had a large impact on all WPAI-GH domains: the work productivity time loss among unvaccinated and vaccinated was 65.0% and 53.8%, and

the mean activity impairment was 50.2% and 43.9%, respectively. With the exception of
absenteeism at Week 4, the BNT162b2 cohort was associated with statistically significant less
worsening in all WPAI-GH scores at both Week 1 and 4.

Conclusions: COVID-19 negatively impacted HRQoL and work productivity among mildly
symptomatic outpatients. Compared with unvaccinated, those vaccinated with BNT162b2 were
less impacted by COVID-19 infection and recovered faster.

Keywords: COVID-19, SARS-CoV-2, HRQoL, WPAI, Quality of Life, COVID-19 symptoms,

55

BNT162b2, humanistic

BACKGROUND

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

The impact of the COVID-19 pandemic on the sustainability of quality of life of patients has been reported globally [1-4]. The prolonged multisystem symptoms associated to SARS-CoV-2 infection can negatively affect daily activities, ability to work, and social interactions, leading to poor health-related quality of life (HRQoL) [1-4]. The introduction of COVID-19 vaccination has significantly impacted the COVID-19 response, and evidence regarding the efficacy, safety and effectiveness of vaccination is extensive [5]. However, there is limited research on the potential benefits of vaccination on physical, mental, social, emotional functioning and economic well-being. Most of the studies assessing humanistic outcomes of COVID-19 infection have been limited to inpatients [1, 2, 6] were conducted outside of the US or focused on specific disease states and organ-specific functions [7-9]. Leveraging a US national retail pharmacy SARS-CoV-2 test database and using validated patient-reported outcome measures (PROMs), this study assessed COVID-19 symptoms, HRQoL and WPAI prior to through one month following SARS-CoV-2 infection in outpatients, and compared results between unvaccinated individuals and those vaccinated with BNT162b2. **METHODS Study Design and Participants** The source population consisted of individuals testing for SARS-CoV-2 at one of ~5,000 CVS Health test sites across the US. As part of the registration process for scheduling a SARS-CoV-2 test at CVS Health, individuals are required to complete a screening questionnaire including demographics, symptoms, comorbidities, and vaccination status. The screening variables and

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

RT-PCR test results are loaded in an analytic dataset, where ~80-90% of test results are reported within 2-3 days. Leveraging this analytic platform, this study was designed as a prospective survey-based patient-reported outcomes study targeting adults >18 with a positive RT-PCR test result and self-reporting at least one symptom. These individuals were emailed an invitation as soon as the test results became available, no later than 4 days from testing. The email invitation directed the potential participants to an e-consent website to learn about the study, survey schedule and informed consent. Figure 1 summarizes the study design. Recruitment of participants was carried out between 01/31/2022 and 04/30/2022 (Ct.gov NCT05160636). **Data Sources and Variables** Baseline characteristics and symptoms Baseline characteristics of the participants were obtained via the CVS Health pre-test screening questionnaire. These included self-reported demographics, comorbidities (including immunocompromised status), COVID-19 vaccination history, social determinants of health including the Social Vulnerability Index (SVI), work and/or residency in a high-risk or healthcare setting, and symptoms. The list of baseline COVID-19 symptoms was based on the CDC [10]. Exposure groups Immunocompetent participants were considered fully vaccinated with BNT162b2 if they selfreported receipt of 2 doses of BNT162b2 ≥ 14 days of SARS-CoV-2 testing. They were considered partially vaccinated if reporting receipt of a single dose and boosted if reporting receipt of 3 doses. Participants self-reporting an immunocompromising condition and receipt of

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

3 doses were considered fully vaccinated (i.e., 3-dose primary series completion); if reporting 4 doses, they were considered boosted. Participants were considered unvaccinated if they did not report any COVID-19 vaccine dose prior to testing. Heterologous schedules were excluded. **HROoL** To assess HRQoL, we used the validated EQ-5D-5L questionnaire [11, 12]. On the day of enrollment, consented participants completed the EQ-5D-5L questionnaire twice, using two versions: a modified version where all the questions were past tense to retrospectively assess pre-COVID-19 baseline QoL, and the standard version in present tense to assess current QoL. To minimize responder bias, the order of administration of the two versions was random. Subsequent completion was requested at one month (short-term study design in Figure 1). The EQ-5D-5L results at each time point were converted into the Utility Index (UI) using the USbased weights by Pickard et al [12, 13]. Work Productivity and Activity Impairment To measure impairments in both paid work and unpaid work, we used the Work Productivity and Activity Impairment General Health V2.0 (WPAI:GH) measure [14, 15]. Participants were asked to complete this questionnaire twice, seven days after their RT-PCR test: once referencing seven days prior to COVID-19 symptom onset and an additional assessment referencing the past seven days. Similar to the EQ-5D-5L, subsequent completion of the WPAI was requested at one month (Figure 1). Four WPAI scores were computed at each time point: percent of worktime missed (absenteeism), percent of impairment while working (presenteeism), percent of work

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

productivity loss (considering both absenteeism and presenteeism), and percent of activity impairment. Only employed subjects were included for work productivity analyses. Post-COVID 19 Symptoms and Vaccination Status Update To supplement the pre-test screening questionnaire and enable the collection of on-going or new symptoms after the acute phase, participants were sent an additional survey four weeks following the test asking to complete a checklist of COVID-19 related symptoms based on the CDC list [16], To confirm vaccination status, participants' subsequent responses to vaccination date questions were compared with their index responses; if responses did not match, the information was queried and adjudicated, and the latest information was typically used. **Statistical Analysis** Descriptive statistics were used to analyze participant characteristics at baseline. Continuous variables were described using means and standard deviations. Categorical variables were reported using number and percentage distributions. For continuous variables, t-tests were used to test difference in means and Wilcoxon tests were used to test difference in medians. For categorical variables, chi-square tests were used to test differences between groups When cell frequency was less than 5, Fisher's exact tests were used for 2-by-2 tables and Freeman-Halton tests for r-by-c tables [17, 18]. P values were all two-sided and not adjusted for multiplicity. Mixed models for repeated measures (MMRM) [19] were used to estimate the magnitude of COVID-19 impact on HRQoL and WPAI over time. Models included variables of time, selfreported SARS-CoV-2 vaccination status, and interaction of time by vaccination status, as well as covariates of participant pre-COVID-19 symptom onset score, sociodemographic

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

characteristics (age, sex, regions, social vulnerability, race/ethnicity, high risk occupations), previously tested positive for COVID-19, severity of acute illness (number of symptoms reported on index date), and immunocompromised status. Assessment time was fitted as a categorical covariate and a repeated effect (repeated by subject). Least squares mean (LS mean) and standard errors of PRO scores for each time point of assessment were calculated. Per guidelines, no adjustment was made for missing data when scoring the EQ-5D-5L UI and WPAI [11, 15]. Missing data at each time were not imputed. All available data were included in the analysis. Cohen's d, or a variation of it, was calculated to assess the magnitude of score change from baseline within the BNT162b2 vaccinated cohort and, separately, the unvaccinated cohort, as well as the difference between BNT162b2 and unvaccinated cohorts [20, 21]. Specifically, within-cohort effect size (ES) was calculated as mean change from baseline to follow-up, divided by the standard deviation of change scores from baseline to follow-up. Between-cohort ES was calculated as the difference in mean changes from baseline between cohorts, divided by the pooled standard deviation of change scores. When calculating model based ESs, the numerators were the predicted mean change from the model for within-cohort ESs, and predicted differences from the model for between-cohort ESs. Denominators were the corresponding observed standard deviations. Values of 0.2, 0.5, and 0.8 standard deviation (SD) units represent small, medium, and large ES, respectively. These cut-off estimates have been widely used to establish important differences in HRQoL studies [22]. As such, we considered the magnitude of (standardized) effect sizes of at least 0.20 SD units as important or meaningful differences in gauging the magnitude of within-patient change and between-group differences. All data obtained were collected and analyzed with SAS Version 9.4 (SAS Institute, Cary, NC). The

study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline [23].

RESULTS

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Baseline characteristics

A total of 39,889 eligible candidates were outreached. Of those, 676 consented and completed the first survey, for a consent rate of 1.7%. Compared with individuals in the CVS Health analytic dataset who did not participate in our study, the study sample was over-represented by women and Caucasians, with slightly more individuals vaccinated and with comorbidities (Supplemental Table 1). The final study population included 430 subjects (Figure 2). 100% completed the EQ-5D-5L questionnaire at pre-COVID-19 baseline and at Day 3, and 77.0% completed it at Week 4. The WPAI-GH questionnaire was completed by 88.1% of the participants at pre-COVID-19 baseline, 88.1% at Week 1 and 76.9% at Week 4. The sociodemographic characteristics of the baseline participants are shown in Table 1. Overall, the mean (SD) age was 42.4 (14.3), 76% were female, 68.6% Caucasian, 58.7% from Southern US. There were 24.2% participants who reported ≥1 comorbidities, including 4.4% with immunocompromising conditions and 39% reported a previous COVID-19 infection. About 46% (197) were unvaccinated and 54% (233) were vaccinated with BNT162b2; of those, respectively 140 (60%) and 93 (40%) received 2 and 3 doses. Compared with unvaccinated, BNT162b2 participants were comparable with respect to gender, working and living settings, and comorbidities, slight older with mean age 43.7 vs. 40.9 (p=0.049); living in less vulnerable area with lower mean social vulnerability index (0.40 vs. 0.49, P<<0.001); and slight differences in

race/ethnicity and region. In the vaccinated group, mean (SD) time since vaccination before infection was 186 (105) days. At index date, the most reported acute symptoms were respiratory and systemic. BNT162b2 vaccinated participants reported fewer overall acute COVID-19 symptoms on average than unvaccinated participants, mean 5.1 vs. 5.6, P=0.034 (Table 1). Directionally, the proportions of all systemic and GI-related symptoms were numerically lower in the BNT162b2 cohort. Relative to unvaccinated, those vaccinated with BNT162b2 reported significantly fewer symptoms of fever (30.5% vs. 47.2% P<0.001), chills (42.9% vs. 57.4%, P=0.003), muscle or body aches (49.4% vs. 59.4%, P=0.038), and diarrhea (15.9% vs. 25.9%, P=0.010), but more congestion or runny nose (80.7% vs. 68.0%, P=0.003). **Post-COVID-19 symptoms** At Week 4, the mean number of symptoms was statistically lower in the BNT162B2 cohort (2.5 vs. 3.7, p=0.002). The overall prevalence decreased over time too, especially fever, cough, headache, fatigue, diarrhea, muscle pain; however, ~70% of participants still reported at least 1 post-COVID-19 symptom. Directionally, the proportions of all symptoms were numerically lower in the BNT162b2 cohort. Symptoms of worsening after physical or mental activities (10.3% vs. 20.6%), general pain/discomfort (11.4% vs. 19.4%), change in smell or taste (10.9%) vs. 20.6%), headache (16.0% vs. 25.2%), sleep problems (20.0% vs. 29.7%), mood changes (7.4% vs. 14.8%), memory loss (6.3% vs. 17.4%) and diarrhea (3.4% vs. 11.0%) were statistically significant (P < 0.05) (Table 2).

Health-Related Quality of life

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Utility Index scores Mean pre-COVID-19 baseline UIs did not differ between the BNT162b2 and unvaccinated cohorts, respectively 0.924 and 0.918 (P=0.547). COVID-19 infection had a detrimental effect on the HRQoL of participants, especially during the acute episode (Day 3). In both the BNT162b2 and the unvaccinated cohorts, UIs were lower at Day 3 and Week 4 relative to pre-COVID-19. While UIs improvement was observed over time, the UI did not return to pre-COVID levels at Week 4 (Table 3). The BNT162B2 cohort was less impacted than the unvaccinated cohort, at both Day 3 and Week 4. After controlling for pre-COVID baseline score and other covariates, the least-square estimate UI scores at Day 3 were, respectively 0.77 and 0.84 in the unvaccinated and BNT162B2 cohorts (Table 4). Moderate ESs of, respectively, 0.64 and 0.49 were observed from baseline. At Week 4, the least-square estimate UI scores were, respectively, 0.86 and 0.90. Small-to-moderate ESs of, respectively, 0.38 and 0.13 were observed from baseline. The differences between the two groups were statistically significant (P<0.05). (Table 4) Small-to-medium ESs between cohorts were observed and were 0.36 and 0.32 for Day 3 and Week 4, respectively. (Table 4, Supplemental Figure 1 and 2) EQ-VAS The pattern of EQ-VAS scores was similar to that observed for UIs. Mean pre-COVID-19 baseline EQ-VAS were similar for the BNT162b2 and unvaccinated cohorts, respectively 86.9 and 87.8 (P=0.414) (Table 3). Similar to the UIs, the pre-COVID EQ-VAS were rated relatively high by the participants, indicating a generally healthy cohort. The least-square estimate EQ-VAS scores for the BNT162b2 and unvaccinated cohorts were, respectively, 76.2 and 72.6 at

Day 3 and 85.0 and 81.6 at Week 4. After controlling for pre-COVID-19 baseline score and other covariates, the least-square estimates of change from pre-COVID-19 baseline in EQ VAS for the BNT162B2 and the unvaccinated cohort were -11.1 and -14.8, respectively on Day 3, and -2.3 and -5.7, respectively at Week 4. COVID-19 had a large adverse impact on EQ-VAS with an ES of -0.89 for BNT162B2 cohort and -0.86 for Unvaccinated cohort on Day 3, and small ES (-0.22) for BNT162B2 cohort and approaching medium ES (-0.42) for Unvaccinated cohort at Week 4. BNT162B2 cohort was associated with 3.6 (P=0.013) on Day 3 and 3.4 (P=0.016) at Week 4 less drop in EQ VAS than the Unvaccinated cohort. The ESs between cohorts were small yet relevant, being 0.25 and 0.28 for Day 3 and Week 4, respectively (Table 4, Supplemental Figure 1 and 2). *EQ-5D-5L dimensions* The health status of the study participants according to the dimensions of EQ-5D-5L is reported in Figure 3 and Supplemental Table 2. In both groups, at Day 3, over half of the cohort reported problems in usual activities, pain/discomfort and anxiety/depression, while the vast majority reported no or slight problems in mobility and self-care. At Week 4, the vast majority continued to report no or slight problems with mobility, self-care, as well as for usual activities; most reported no, slight or moderate problems with pain/discomfort and anxiety/depression. BNT162b2 cohort had lower mean responses across all 5 domains at both Day 3 and Week 4 relative to unvaccinated.

Work Productivity and Activity Impairment

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

Approximately 65% of participants reported being currently employed at baseline (155 in the BNT162b2 cohort and 129 unvaccinated), and were eligible to complete the absenteeism, presenteeism and work-productivity loss questions. At Week 1, COVID-19 had a large impact on all four WPAI-GH domains for both the unvaccinated and BNT162b2cohort. The mean time loss due to absenteeism was, respectively, 65.0% and 45.6%; the mean time loss due to presenteeism was, respectively, 46.8% and 38.4%; the mean time of work productivity loss was 65.0% and 53.8%, and the mean time of activity impairment was 50.2% and 43.9%. All within-cohort ESs were > 0.8, which are considered large effects (Table 3). After controlling for pre-COVID-19 baseline score, and other covariates, the BNT162b2 cohort was associated with less worsening in WPAI-GH scores. Small-to-medium ESs were observed for work-related scores (absenteeism -0.50, presenteeism -0.26, and work productivity loss -0.32) between the BNT162b2 cohort and the unvaccinated cohort (Table 4). At Week 4, the mean time loss dropped across all four domains. The time loss due to absenteeism dropped substantially; the change from baseline in absenteeism was not found to be statistically significant between the BNT162b2 cohort and the unvaccinated cohort. Small-to-medium ESs were observed for presenteeism (-0.38) work productivity loss (-0.29), and activity impairment (-0.34) between the BNT162b2 cohort and the unvaccinated cohort (Table 4, Supplemental Figure 3 and 4).

DISCUSSION

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

- The impacts of SARS-CoV-2 infection go beyond its clinical outcomes.
- We found that mild acute infection can negatively impact the humanistic outcomes for up to four
- 280 weeks post infection. Shortly after infection, the UI and EQ-VAS HRQoL scores dropped from
- pre-COVID, and over half of the study population reported problems in usual activities,

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

pain/discomfort and anxiety/depression. At Week 1, the work productivity and activity impairment time loss were over 50%. At Week 4, both the HRQoL and WPAI scores improved, although they did not return to pre-COVID levels. Individuals vaccinated with BNT162b2 were less impacted and recovered faster than unvaccinated individuals. Multivariable analyses showed that BNT162b2 was significantly associated with higher EQ-VAS and UI scores, less symptoms and better WPAI scores, except for absenteeism at Week 4. There is limited evidence measuring the health-related wellbeing of non-hospitalized individuals affected by COVID-19 [1-4]. To our knowledge, this is the first report measuring the impact of COVID-19 on the HRQoL and WPAI among a national sample of outpatients in the United States. In contrast to our study, previous research that used EQ-5D scales to measure COVID-19 impact on the HRQoL reported mean UI scores ranging from 0.61 to 0.86 depending on the hospitalization treatment and time since discharge [1, 2]. The EQ-VAS scores ranged from 50.7 to 70.3 [1, 2]. In our study, the HRQoL scores at Day 3 and Week 4 among outpatients with mild disease are higher than those, likely due to the different study populations and periods. In a small US study assessing the impact of COVID-19 on WPAI ~4 months post-infection among subjects enrolled in clinical trials before the introduction of vaccines, 46% of the non-hospitalized patients reported health-related impairment in daily activities [24]. Among the employed, 11.5% missed work and 38.9% reported impairment at work due to health. In our study, all the WPAI scores among unvaccinated at Week 1 are higher, and those at Week 4 similar or lower than those, likely due to the different cut-off, study populations, periods and design. HRQoL and WPAI studies are scarce in COVID-19 related vaccination research. To our knowledge, this is the first report on the effects of BNT162b2 on these patient-centric outcomes.

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

These results indicate an additive benefit beyond vaccine effectiveness that should be explored further. Strengths of this study include the nationally representative real-world source population of mildly symptomatic outpatients, the prospective collection of the primary outcomes via validated instruments, and the representativeness of the employed population for work productivity analyses (\sim 65% of the cohort). The age distribution of study participants was comparable with the non-enrolled tested population (p=0.076 for mean age, Supplemental Table 1) and with CDC research in non-hospitalized adults: 91.6% were between 18 and 64 and 8.4% were 65 or older, which was quite similar to Hernandez-Romieu [25], 92.7% and 7.3%, respectively. In the vaccinated group, the time between vaccination and breakthrough infection (mean: ~6 months) was consistent with literature on vaccine-induced duration of protection [5]. The study findings are subject to limitations. All the data analyzed was self-reported and may be subject to error, missingness, recall bias, social desirability bias, and selection bias associated with survey drop-out. Out of 430 participants completing Day 3 survey, 12% (51/430) missed Week 1 and 23% (99/430) missed Week 4 survey. The drop in responses may partly be the result of responders' fatigue, and/or recovered cases not returning to follow-up surveys. Female and older age (≥30 years) were found to be more likely to miss follow-up surveys. However, after taking into account several variables, the model predicting missingness indicated that missingness was not associated with vaccination status, nor with HRQoL in terms of EQ VAS on Day 3 and its change from pre-COVID-19 baseline (Supplemental Table 3). The study population differed from non-enrolled tested outpatients in being predominantly female, white, with a higher vaccination uptake, and slightly more comorbidities (Supplemental Table 1). The female over-representation is in line with prior research indicating that women are

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

more likely to contribute to health research surveys [2]. In our study, ~24% of participants reported at least one comorbidity, in contrast to 20% among the non-enrolled tested and ~35% in Hernandez-Romieu (2021) [25]. Various models were fit to account for potential effects due to sociodemographic factors and comorbidities. These adjusted effect sizes between BNT162b2 and unvaccinated cohorts were similar and consistent with those calculated from observed data (unadjusted effect sizes). The pre-COVID baseline scores were slightly higher than US population norms. The mean EQ-VAS and UI were 86.9 and 0.924 for the BNT162b2 cohort, and 87.8 and 0.918 for the unvaccinated cohort, respectively. Cha et al (2019) reported a mean EQ-VAS of 84.6 for the U.S. general population [12]. Jiang et al (2021) reported the US population norm of EQ-VAS as 80.4 and the mean EQ-5D-5L UI as 0.851 [26]. The healthy pre-infection status of the study population and the potential for retrospective recall bias may partially explain the differences. A modified EQ-5D-5L questionnaire was used to retrospectively measure pre-COVID-19 baseline data; despite literature suggesting concordance between prospective and retrospective measurements of EQ-5D-5L [27, 28], and a good correlation between assessment of baseline before the index date and recall assessment of the baseline after index date, there is currently no information regarding the recall application of the EQ-5D-5L for COVID-related studies. The pre-COVID-19 values for absenteism and presenteeism were 3.1% and 9.5% in the BNT162b2 cohort, and were generally in line with Tundia et al (2015) [29], whom reported 4% absenteeism and 10% presenteeism for the US general population. The reported values were slightly higher among unvaccinated, respectively 11.7% and 9.4%.

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

There is currently no standard definition of minimal clinically important difference of PROs in COVID-19 research. We used effect size (ES) of Cohen's d to quantify the magnitude of score change from baseline within the BNT162b2 vaccinated cohort and the unvaccinated cohort, as well the difference between these two cohorts [20]. An effect size ES of 0 between groups indicates that the average (typical) treated vaccinated person has a score that is no different from the typical control person; equivalently, scores of the typical treated person are more favorable than 50% of the individual scores in the control group, meaning no incremental benefit (a coin toss as to which intervention is better). If the vaccinated cohort is presumed more effective than the unvaccinated cohort, effect sizes thresholds of 0.2, 0.3, 0.5, and 0.8 (in absolute value) indicate that, based on the standardized normal distribution, the score of the typical person in the vaccinated cohort is more favorable than 58% (8% incremental benefit), 62% (12% incremental benefit), 69% (19% incremental benefit), and 70% (29% increment benefit) of the scores from individuals in the unvaccinated cohort. For example, from baseline to Week 1, the increase in the absenteeism WPAI score of the typical person in the vaccinated cohort was less (more favorable) than the corresponding change in 69% of individuals in the unvaccinated group (effect size = -0.5). Depending on the type of outcome, the same type of effect size interpretation for between cohorts can be given within cohort. For instance, from baseline to Week 4, the quality of life EQ-VAS score of the typical person in the vaccine cohort at Week 4 was less (worse) than 59% of the individual scores in the vaccine cohort at baseline (effect size = -0.22); the quality of life EQ-VAS score of the typical person in the unvaccinated cohort at Week 4 was less (worse) than 66% of the individual scores in the unvaccinated cohort at baseline (effect size = -0.42).

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

The study did not assess the impact on pediatrics, caregivers, long-term outcomes (e.g., "Long COVID"), and the data was collected during Omicron predominance in the US. Therefore, these findings may not be generalizable to prior or future variants, other countries, time periods and populations that were excluded. COVID-19 sequalae can affect a substantial portion of patients, with long-term consequences for their health, continuity of care and ability to work [1, 2]. Persistent symptoms and work impairment were reported ~4 months after infection among nonhospitalized US patients enrolled in clinical trials [24]. Continued follow-up studies covering longer time periods may inform whether the protection provided by COVID-19 vaccination extends beyond the acute phase. Only generic PROMs were used in this study; COVID-19 disease-specific instruments are under development [30, 31], warranting research on their implementation. The PROMs omitted questions on vaccine adverse events. The mean 6-month interval between vaccination and breakthrough infection and a medical review ruled out cases of residual symptoms from vaccination. Research on the impact of vaccine adverse events on HRQoL is warranted. Lastly, the study adopted an observational design, which is limited in establishing causal relationships. Future studies using different data collection methods could corroborate the study findings, including those with more rigorous study design. Consistent with literature, our study found that COVID-19 is detrimental to mildly symptomatic COVID-19 patients. The findings provide a meaningful contribution suggesting that the ability of BNT162b2 to reduce adverse outcomes from COVID-19 disease can translate to lessening the broad impact of COVID-19 and improvements in quality of life, work productivity and activity.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

CONCLUSION This study found that mild COVID-19 infection at a time of Omicron predominance adversely impacted the HROoL, daily activity and work productivity of patients. This detrimental effect improved over time, although it persisted for at least one month post infection. Compared with unvaccinated, those vaccinated with BNT162b2 were less impacted and recovered faster. These findings advance research on COVID-19 associated humanistic outcomes and the potential effect of BNT162b2 in lessening the loss of HRQoL, daily activity and work productivity due to COVID-19. The results can inform the estimation of quality-adjusted life years and indirect cost savings in health economic studies. **List of Abbreviations** CDC: Centers for Disease Control and Prevention; CI: Confidence interval; EQ-5D-5L: EuroQoL Group 5 dimension and 5 level questionnaire; ES: Effect size; GH: General Health; HRQoL: Health Related Quality of Life; MMRM: Mixed models for repeated measures; SD: standard deviation; SE: standard error; STROBE: the Strengthening the Reporting of Observational Studies in Epidemiology; UI: utility index; VAS: Visual analogue scale; WPAI: Work Productivity and Impairment. **DECLARATIONS:** Ethics Approval and consent to participate This study was approved by the Sterling IRB, Protocol #C4591034. Participation in the study was voluntary and anonymous. Consent was obtained electronically via the CVS Health E-

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

Consent platform. Participants were informed of their right to refuse or withdraw from the study at any time. Participants were compensated for their time. **Consent for publication** All authors have given their approval for this manuscript version to be published. Availability of data and material Aggregated data that support the findings of this study are available upon reasonable request from the corresponding author MDF, subject to review. These data are not publicly available due to them containing information that could compromise research participant privacy/consent. **Competing interests** MDF, MMM, JMZ, LP, MBA and JCC are employees of Pfizer and may hold stock or stock options of Pfizer. XS and HC are employees of CVS Health and may hold stock of CVS health. YPT was employee of CVS Health when current study was conducted. **Funding** This study was sponsored by Pfizer Inc. **Authors' contributions** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. All authors contributed to study conception and design, data acquisition, analysis, and interpretation, drafting and revising of the manuscript. Acknowledgements The authors acknowledge Alejandro Cane, Deepa Malhotra and Nancy Gifford (Pfizer employees), Joseph Ferenchick, Shiyu Lin and Shawn Edmonds (CVS Health employees) for specific contributions to this research project. Editorial support was provided by Laura Anatale-Tardiff and Leena Samuel at CVS Health and was funded by Pfizer.

REFERENCES

438

439

- Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, Ziauddeen N, Yao GL
 (2021) Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS One. 16(10):e0259164.
- 2. Nandasena H, Pathirathna M, Atapattu A, Prasanga P (2022) Quality of life of COVID 19 patients after discharge: Systematic review. PloS one. 17(2):e0263941.
- Figueiredo EAB, Silva WT, Tsopanoglou SP, Vitorino DFdM, Oliveira LFLd, Silva KLS, Luz HDH, Ávila MR, Oliveira LFFd, Lacerda ACR (2022) The health-related quality of life in patients with post-COVID-19 after hospitalization: a systematic review. Revista da Sociedade Brasileira de Medicina Tropical. 55.
- 4. Amdal CD, Pe M, Falk RS, Piccinin C, Bottomley A, Arraras JI, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH (2021) Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. Quality of Life Research. 30(12):3367-81.
- International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health,
 World Health Organization. Results of COVID-19 Vaccine Effectiveness & Impact
 Studies: An Ongoing Systematic Review. https://view-hub.org/sites/default/files/2022-456
 Od/COVID19 VE and Impact Lit Review Methods.pdf Accessed August 15, 2022.
- 457 6. Arab-Zozani M, Hashemi F, Safari H, Yousefi M, Ameri H (2020) Health-related quality 458 of life and its associated factors in COVID-19 patients. Osong public health and research 459 perspectives. 11(5):296.
- Petersen EL, Goßling A, Adam G, Aepfelbacher M, Behrendt C-A, Cavus E, Cheng B,
 Fischer N, Gallinat J, Kühn S (2022) Multi-organ assessment in mainly non-hospitalized
 individuals after SARS-CoV-2 infection: the Hamburg City Health Study COVID
 programme. European Heart Journal. 43(11):1124-37.
- McKay SC, Lembach H, Hann A, Okoth K, Anderton J, Nirantharakumar K, Magill L,
 Torlinska B, Armstrong M, Mascaro J (2021) Health related quality of life, uncertainty
 and coping strategies in solid organ transplant recipients during shielding for the
 COVID 19 pandemic. Transplant International. 34(11):2122-37.
- Talman S, Boonman-de Winter L, De Mol M, Hoefman E, Van Etten R, De Backer I
 (2021) Pulmonary function and health-related quality of life after COVID-19 pneumonia.
 Respiratory Medicine. 176:106272.
- 10. Centers for Disease Control and Prevention. Updates Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html Accessed

473 August 1 2021.

- 474 11. EuroQol Research Foundation. (2019) EQ-5D-5L User Guide, Version 3.0. https://euroqol.org/publications/user-guides Accessed August 5, 2021.
- Cha AS, Law EH, Shaw JW, Pickard AS (2019) A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017. Quality of Life Research.
 28(11):3065-9.


- 479 13. Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL (2019) United States valuation of EQ-5D-5L health states using an international protocol. Value in Health. 22(8):931-41.
- 482 14. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 4(5):353-65.
- 484 15. Reilly Associates. (2002) WPAI Scoring.
 485 http://www.reillyassociates.net/WPAI Scoring.html Accessed August 5, 2021.
- 486 16. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions.
- 487 https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html Accessed August 15, 2022.
- 489 17. Rosner B (2015) Fundamentals of biostatistics. Cengage learning,
- 490 18. Freeman G, Halton JH (1951) Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 38(1/2):141-9.
- 492 19. Fitzmaurice GM, Laird NM, Ware JH (2012) Applied longitudinal analysis. John Wiley
 493 & Sons, Hoboken, NJ
- 494 20. Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd ed. Lawrence Erlbaum Assoc, Hillsdale, NJ.
- 496 21. McLeod LD, Cappelleri JC, Hays RD (2016) Best (but oft-forgotten) practices: 497 expressing and interpreting associations and effect sizes in clinical outcome assessments. 498 The American journal of clinical nutrition. 103(3):685-93.
- Mouelhi Y, Jouve E, Castelli C, Gentile S (2020) How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Health and Quality of Life Outcomes. 18(1):1-17.
- 502 23. STROBE Statement—Checklist of items that should be included in reports of cohort studies. https://www.strobe-statement.org/download/strobe-checklist-cohort-studies-pdf Accessed August 5, 2022.
- Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, Singh U,
 Jagannathan P, Grant P (2021) Patients with uncomplicated COVID-19 have long-term
 persistent symptoms and functional impairment similar to patients with severe COVID19: a cautionary tale during a global pandemic. Clinical Infectious Diseases. doi:
 10.1093/cid/ciab103.
- Hernandez-Romieu AC, Leung S, Mbanya A, Jackson BR, Cope JR, Bushman D, Dixon M, Brown J, McLeod T, Saydah S (2021) Health care utilization and clinical characteristics of nonhospitalized adults in an integrated health care system 28–180 days after COVID-19 diagnosis—Georgia, May 2020–March 2021. Morbidity and Mortality Weekly Report. 70(17):644.
- 515 26. Jiang R, Janssen M, Pickard AS (2021) US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Quality of Life Research. 30(3):803-16.
- Lawson A, Tan AC, Naylor J, Harris IA (2020) Is retrospective assessment of healthrelated quality of life valid? BMC Musculoskeletal Disorders. 21(1):1-10.
- Rajan SS, Wang M, Singh N, Jacob AP, Parker SA, Czap AL, Bowry R, Grotta JC,
 Yamal JM (2021) Retrospectively Collected EQ-5D-5L Data as Valid Proxies for
- Imputing Missing Information in Longitudinal Studies. Value Health. 24(12):1720-7. doi: 10.1016/j.jval.2021.07.007.

- Tundia N, Hass S, Fuldeore M, Wang LL, Cavanaugh T, Boone J, Heaton P (2015)
 Validation and US population norms of health-related productivity questionnaire. Value in Health. 18(3):A24.
- Romano C, Fehnel S, Stoddard J, Sadoff J, Lewis S, McNulty P, Chan EK, Evans E,
 Jamieson C, Slagle AF (2022) Development of a novel patient-reported outcome measure
 to assess signs and symptoms of COVID-19. Journal of Patient-Reported Outcomes.
 6(1):1-12.
- Hughes SE, Haroon S, Subramanian A, McMullan C, Aiyegbusi OL, Turner GM, Jackson L, Davies EH, Frost C, McNamara G (2022) Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ. 377.

Figure 1. Study design ^a

535

537538



^a QoL refers to the EQ-5D-5L survey

Figure 2. Study flow diagram




Table 1 Patient Characteristics on Index Day

	All	BNT162b2	Unvaccinated	P-value ^a
Total, n	430	233	197	
Age, years				
Mean, SD	42.4 (14.3)	43.7 (15.3)	40.9 (12.9)	0.049
18-29	87 (20.2%)	49 (21.0%)	38 (19.3%)	0.011
30-49	213 (49.5%)	100 (42.9%)	113 (57.4%)	
50-64	94 (21.9%)	60 (25.8%)	34 (17.3%)	
≥65	36 (8.4%)	24 (10.3%)	12 (6.1%)	
Gender	, ,		•	0.966
Female	327 (76.0%)	177 (76.0%)	150 (76.1%)	
Male	103 (24.0%)	56 (24.0%)	47 (23.9%)	
Race / Ethnicity	, ,		, ,	0.026
White or Caucasian (not Hispanic or Latino)	295 (68.6%)	166 (71.2%)	129 (65.5%)	
Black or African American	20 (4.7%)	7 (3.0%)	13 (6.6%)	
Hispanic	61 (14.2%)	35 (15.0%)	26 (13.2%)	
Asian	22 (5.1%)	15 (6.4%)	7 (3.6%)	
Patient Refused	13 (3.0%)	5 (2.2%)	8 (4.1%)	
Other	19 (4.4%)	5 (2.2%)	14 (7.1%)	
CMS Geographic Region (n, %)				0.009
Region 1: ME, NH, VT, MA, CT, RI	19 (4.4%)	10 (4.3%)	9 (4.6%)	
Region 2: NY, NJ, PR, VI	11 (2.6%)	7 (3.0%)	4 (2.0%)	
Region 3: PA, DE, MD, DC, WV, VA	37 (8.6%)	22 (9.4%)	15 (7.6%)	
Region 4: KY, TN, NC, SC, GA, MS, AL, FL	156 (36.3%)	81 (34.8%)	75 (38.1%)	
Region 5: MN, WI, IL, MI, IN, OH	58 (13.5%)	31 (13.3%)	27 (13.7%)	
Region 6: NM, OK, AR, TX, LA	82 (19.1%)	56 (24.0%)	26 (13.2%)	
Region 7: NE, IA, KS, MO	19 (4.4%)	11 (4.7%)	8 (4.1%)	
Region 8 : MT, ND, SD, WY, UT, CO	1 (0.2%)	1 (0.4%)	0 (0.0%)	
Region 9: CA, NV, AZ, GU	46 (10.7%)	13 (5.6%)	33 (16.8%)	
Region 10: AK, WA, OR, ID	1 (0.2%)	1 (0.4%)	0 (0.0%)	
U.S. Geographic Region				0.005
Northeast	53 (12.2%)	29 (12.3%)	24 (12.2%)	
South	254 (58.7%)	150 (63.6%)	104 (52.8%)	
Midwest	77 (17.8%)	42 (17.8%)	35 (17.8%)	
West	49 (11.3%)	15 (6.4%)	34 (17.3%)	
Previously Tested Positive	167 (38.8%)	89 (38.2%)	78 (39.6%)	0.589

	All	BNT162b2	Unvaccinated	P-value a
Work in healthcare	47 (10.9%)	29 (12.4%)	18 (9.1%)	0.309
Work in high-risk setting	44 (10.2%)	30 (12.9%)	14 (7.1%)	0.158
Live in high-risk setting	22 (5.1%)	12 (5.2%)	10 (5.1%)	0.553
Social vulnerability index				
Mean (SD)	0.44 (0.22)	0.40 (0.22)	0.49 (0.21)	< 0.001
Median (Q1, Q3)	0.41 (0.27, 0.59)	0.37 (0.23, 0.55)	0.47 (0.31, 0.63)	< 0.001
Self-Reported Comorbidity				
Asthma or Chronic Lung Disease	34 (7.9%)	21 (9.0%)	13 (6.6%)	0.355
Cirrhosis of the liver	1 (0.2%)	1 (0.4%)	0 (0.0%)	1.0000
Immunocompromised Conditions or Weakened Immune System ^c	19 (4.4%)	12 (5.2%)	7 (3.6%)	0.422
Diabetes	20 (4.7%)	13 (5.6%)	7 (3.6%)	0.320
Heart Conditions or Hypertension	52 (12.1%)	30 (12.9%)	22 (11.2%)	0.588
Overweight or obesity	19 (4.4%)	12 (5.2%)	7 (3.6%)	0.422
At least 1 comorbidity	104 (24.2%)	61 (26.2%)	43 (21.8%)	0.294
Number of comorbidities, Mean (SD)	0.34 (0.68)	0.38 (0.75)	0.28 (0.58)	0.138
Index day b acute COVID-19 sym	ptoms			
Systemic symptoms				
Fever	164 (38.1%)	71 (30.5%)	93 (47.2%)	< 0.001
Chills	213 (49.5%)	100 (42.9%)	113 (57.4%)	0.003
Muscle or Body Aches	232 (54.0%)	115 (49.4%)	117 (59.4%)	0.038
Headache	293 (68.1%)	153 (65.7%)	140 (71.1%)	0.231
Fatigue	266 (61.9%)	141 (60.5%)	125 (63.5%)	0.532
Respiratory symptoms				
Shortness of Breath or Difficulty Breathing	54 (12.6%)	25 (10.7%)	29 (14.7%)	0.213
Cough	309 (71.9%)	168 (72.1%)	141 (71.6%)	0.903
Sore Throat	238 (55.3%)	134 (57.5%)	104 (52.8%)	0.327
New/Recent Loss of Taste or Smell	45 (10.5%)	23 (9.9%)	22 (11.2%)	0.662
Congestion or Runny Nose	322 (74.9%)	188 (80.7%)	134 (68.0%)	0.003
GI symptoms				
Nausea or Vomiting	55 (12.8%)	24 (10.3%)	31 (15.7%)	0.093
Diarrhea	88 (20.5%)	37 (15.9%)	51 (25.9%)	0.010
Number of acute COVID-19 symptoms, Mean (SD)	5.3 (2.6)	5.1 (2.4)	5.6 (2.7)	0.034

^a P value refers to the comparison between BNT162B2 and Unvaccinated.

^b COVID-19 test nasal swab day

544

547

548

545 c Immunocompromised conditions includes compromised immune system (such as from

546 immuno-compromising drugs, solid organ or blood stem cell transplant, HIV, or other

conditions), conditions that result in a weakened immune system, including cancer treatment,

and kidney failure or end stage renal disease

Table 2 Post-COVID-19 Symptoms at Week 4

549

Symptom	All	BNT162b2	Unvaccinated	P-value a
General symptoms				
Tiredness or fatigue	136 (41.2%)	71 (40.6%)	65 (41.9%)	0.802
Symptoms that get worse after physical or mental activities	50 (15.2%)	18 (10.3%)	32 (20.6%)	0.009
Fever	1 (0.3%)	0 (0.0%)	1 (0.7%)	0.470
General pain/discomfort	50 (15.2%)	20 (11.4%)	30 (19.4%)	0.045
Respiratory and cardiac				
Difficulty breathing or shortness of breath	58 (17.6%)	26 (14.9%)	32 (20.6%)	0.168
Cough	86 (26.1%)	40 (22.9%)	46 (29.7%)	0.159
Chest or stomach pain	32 (9.7%)	14 (8.0%)	18 (11.6%)	0.268
Fast-beating or pounding heart (also known as heart palpitations)	38 (11.5%)	17 (9.7%)	21 (13.5%)	0.276
Neurologic				
Change in smell or taste	51 (15.5%)	19 (10.9%)	32 (20.6%)	0.014
Headache	67 (20.3%)	28 (16.0%)	39 (25.2%)	0.039
Dizziness on standing (lightheadedness)	45 (13.6%)	20 (11.4%)	25 (16.1%)	0.214
Difficulty thinking or concentrating (sometimes referred to as "brain fog")	86 (26.1%)	43 (24.6%)	43 (27.7%)	0.513
Pins-and-needles feeling	24 (7.3%)	10 (5.7%)	14 (9.0%)	0.247
Sleep problems	81 (24.5%)	35 (20.0%)	46 (29.7%)	0.042
Mood changes	36 (10.9%)	13 (7.4%)	23 (14.8%)	0.031
Memory loss	38 (11.5%)	11 (6.3%)	27 (17.4%)	0.002
Other				
Diarrhea	23 (7.0%)	6 (3.4%)	17 (11.0%)	0.007
Joint or muscle pain	67 (20.3%)	29 (16.6%)	38 (24.5%)	0.073
Rash	11 (3.3%)	3 (1.7%)	8 (5.2%)	0.082
Changes in period cycles	28 (11.5%)	12 (9.4%)	16 (13.8%)	0.280
Number of post-COVID-19 symptoms, Mean (SD)	3.1 (3.6)	2.5 (3.0)	3.7 (4.1)	0.002
0	100 (30.3%)	54 (30.9%)	46 (29.7%)	0.001
1-2	100 (30.3%)	59 (33.7%)	41 (26.5%)	
3-5	61 (18.5%)	40 (22.9%)	21 (13.5%)	
6-8	32 (9.7%)	9 (5.1%)	23 (14.8%)	
≥9	37 (11.2%)	13 (7.4%)	24 (15.5%)	

^a P-values of t-test for number of symptoms, chi-square or Fisher's exact tests when any one cell has an expected frequency less than 5 for individual symptoms and number of symptom

category comparing the BNT162b2 cohort and the unvaccinated cohort.

Table 3 Summary of EQ-5D-5L and WPAI-GH Scores^a and Their Changes from Baseline by Assessment Time

			BNT	T162b2 Coho	rt			U ₁	nvacc	cinated Cohor	rt		Difference in Change from		
		Score		Change from	n Baseline	b		Score		Change from	n Baseline	;	Baseline B	etween Co	horts
	n	Mean (SD)	n	Mean (SD)		ES_w^d	n	Mean (SD)	n	Mean (SD)	P-value c	ES _w ^d	Mean (SD)	P-value e	ES _b ¹
EQ-5D-5L															
Visual analogue scale (VAS)															
Baseline ^g	233	86.9 (10.7)					197	87.8 (11.0)						0.414 h	
Day 3	233	73.9 (15.6)	233	-13.0 (12.5)	< 0.001	-1.04	194	71.8 (19.6)	194	-16.1 (17.1)	< 0.001	-0.94	3.1 (14.8)	0.033	0.21
Week 4	171	82.9 (13.8)	171	-3.7 (10.7)	< 0.001	-0.35	151	80.9 (15.7)	151	-7.2 (13.7)	< 0.001	-0.53	3.5 (12.2)	0.011	0.28
Utility Index (US weight)															
Baseline ^e	233	0.924 (0.117)					197	0.918 (0.117)						0.547 h	
Day 3	233	0.820 (0.193)	233	-0.105 (0.159)	<0.001	-0.66	197	0.762 (0.252)	197	-0.155 (0.228)	<0.001	-0.68	0.050 (0.194)	0.007	0.26
Week 4	176	0.882 (0.145)	176	-0.039 (0.120)	<0.001	-0.33	155	0.838 (0.197)	155	-0.074 (0.156)	<0.001	-0.47	0.035 (0.138)	0.023	0.25
WPAI-GH															
Absenteeism															
Baseline ^e	153	2.8 (11.8)					129	11.7 (26.4)						<0.001 h	
Week 1	153	44.9 (38.3)	147	42.5 (38.8)	<0.001	1.09	129	66.7 (37.0)	127	55.5 (39.2)	<0.001	1.42	-13.0 (39.0)	0.006	-0.33
Week 4	128	4.6 (17.2)	122	1.4 (20.1)	0.460	0.07	106	3.3 (12.2)	102	-7.7 (28.1)	0.007	-0.27	9.0 (24.1)	0.006	0.37
Presenteeism															
Baseline ^e	153	9.5 (18.5)					124	9.4 (20.4)						0.958 h	
Week 1	123	41.7 (27.4)	119	33.0 (29.1)	< 0.001	1.13	82	47.8 (34.2)	81	38.2 (35.9)	< 0.001	1.06	-5.1 (32.1)	0.268	-0.16
Week 4	125	11.7 (18.8)	119	1.4 (24.5)	0.527	0.06	105	18.7 (23.4)	96	10.7 (24.1)	< 0.001	0.45	-9.3 (24.3)	0.006	-0.38
Work productivity loss															
Baseline ^e	152	10.5 (20.0)					123	14.2 (24.7)						0.175 h	
Week 1		56.6 (31.5)	118	46.7 (34.5)	< 0.001	1.35		66.9 (32.4)	80	53.2 (35.3)	< 0.001	1.51	-6.4 (34.9)	0.203	-0.18

Week 4	125	12.9 (20.7)	118	1.4 (27.5)	0.589	0.05	105	19.8 (24.6)	96	7.7 (30.6)	0.016	0.25	-6.3 (29.0)	0.113	-0.22
Activity															
impairment															
Baseline ^e	203	12.5 (22.2)					176	17.2 (27.2)						$0.065^{\rm h}$	
Week 1	202	48.6 (29.8)	202	36.1 (31.9)	< 0.001	1.13	176	54.2 (32.7)	176	37.0 (37.5)	< 0.001	0.99	-0.9 (34.6)	0.801	-0.03
Week 4	175	15.5 (21.7)	175	2.3 (26.3)	0.242	0.09	155	25.9 (28.5)	155	8.8 (33.8)	0.002	0.26	-6.4 (30.1)	0.053	-0.21

⁵⁵⁵ ^a Score ranges: EQ-5D-5L VAS 0 to 100, EQ-5D-5L UI (the United States weights) -0.573 to 1; WPAI-GH (absenteeism, 556

presenteeism, work productivity loss, and activity impairment) 0 to 100 percent.

^b Baseline refers to pre-COVID-19 symptom onset.

^c P-value of t-test comparing mean score changes from baseline and 0 within BNT162b2 or Unvaccinated cohorts. 558

⁵⁵⁹ ^d ES_w refers to effect size for score changes from baseline within BNT162b2 or Unvaccinated cohorts.

⁵⁶⁰ ^e P-value of t-test comparing mean score changes from baseline between BNT162b2 and Unvaccinated cohorts.

^f ES_b refers to effect size for score changes from baseline between BNT162b2 and Unvaccinated cohorts. 561

g Prior to symptom onset (pre-COVID). 562

^h P-values of t-tests comparing pre-COVID-19 baseline mean scores between BNT162b2 and Unvaccinated cohorts. 563


Table 4 Least-Square Mean Estimate and 95% Confidence Interval for EQ-5D-5L and WPAI-GH Scores ^a

BN	NT162b2 Cohort			U	Invaccinated Cohor	t		Datassa Ca	land Differ	
Score	Change from	m Baselii	ne	Score	Change from	Baseline	•	Between Co.	nort Diller	ence
LSE (95% CI)	LSE (95% CI)	P-	ES _w ^c	LSE (95% CI)	LSE (95% CI)	P-	ES _w ^c	LSE (95% CI)	P-value d	$\mathrm{ES_{b}}^{\mathrm{e}}$
		varue		<u> </u>	<u> </u>	value				
	1									
76.2 (73.3, 79.2)	-11.1 (-14.1, -	<0.001	-0.89	72.6 (69.7, 75.4)	-14.8 (-17.6, - 11.9)	<0.001	-0.86	3.6 (0.8, 6.5)	0.013	0.25
85.0 (82.1, 87.9)	-2.3 (-5.2, 0.6)	0.119	-0.22	81.6 (78.8, 84.4)	-5.7 (-8.5, -2.9)	< 0.001	-0.42	3.4 (0.6, 6.2)	0.016	0.28
dex (US weight)										
0.842 (0.805, 0.879)	-0.077 (-0.115, -0.040)	< 0.001	-0.49	0.773 (0.736, 0.809)	-0.147 (-0.183, - 0.110)	< 0.001	-0.64	0.069 (0.032, 0.107)	<0.001	0.36
0.903 (0.868, 0.938)	-0.016 (-0.051, 0.019)	0.369	-0.13	0.859 (0.826, 0.892)	-0.060 (-0.093, - 0.027)	< 0.001	-0.38	0.044 (0.013, 0.075)	0.005	0.32
Η		1							'	
ism										
45.6 (38.0, 53.1)	39.1 (31.6, 46.7)	< 0.001	1.01	65.0 (57.5, 72.5)	58.6 (51.1, 66.0)	< 0.001	1.49	-19.4 (-28.3, -10.6)	<0.001	-0.50
5.3 (0.0, 10.7)	-1.1 (-6.5, 4.2)	0.676	-0.06	2.2 (0.0, 7.1) ^f	-4.3 (-9.2, 0.6)	0.086	-0.15	3.2 (-1.1, 7.4)	0.145	0.13
ism										
38.4 (30.3, 46.5)	29.0 (20.8, 37.1)	<0.001	1.00	46.8 (38.6, 55.1)	37.4 (29.1, 45.6)	< 0.001	1.04	-8.4 (-16.7, -0.1)	0.047	-0.26
6.8 (0, 13.9) ^f	-2.7 (-9.7, 4.4)	0.458	-0.11	16.0 (9.4, 22.5)	6.5 (0.0, 13.0)	0.050	0.27	-9.2 (-14.7, -3.6)	0.001	-0.38
ductivity loss										
53.8 (45.1, 62.4)	42.4 (33.8, 51.0)	<0.001	1.23	65.0 (56.2, 73.7)	53.6 (44.8, 62.4)	<0.001	1.52	-11.2 (-19.9, -2.5)	0.012	-0.32
8.6 (0.9, 16.2)	-2.8 (-10.4, 4.9)	0.476	-0.10	17.0 (9.9, 24.0)	5.7 (-1.4, 12.7)	0.116	0.18	-8.4 (-14.5, -2.3)	0.007	-0.29
mpairment										
43.9 (37.7, 50.1)	29.0 (22.8, 35.3)	< 0.001	0.91	50.2 (44.2, 56.2)	35.4 (29.3, 41.4)	< 0.001	0.94	-6.3 (-12.4, -0.2)	0.044	-0.18
	Score LSE (95% CI) Lalogue scale (VAS) 76.2 (73.3, 79.2) 85.0 (82.1, 87.9) dex (US weight) 0.842 (0.805, 0.879) 0.903 (0.868, 0.938) H sm 45.6 (38.0, 53.1) 5.3 (0.0, 10.7) ism 38.4 (30.3, 46.5) 6.8 (0, 13.9) f ductivity loss 53.8 (45.1, 62.4) 8.6 (0.9, 16.2) mpairment	LSE (95% CI) LSE (95% CI) Lalogue scale (VAS) 76.2 (73.3, 79.2) -11.1 (-14.1, -8.2) 85.0 (82.1, 87.9) -2.3 (-5.2, 0.6) dex (US weight) 0.842 (0.805, 0.077 (-0.115, 0.879) -0.040) 0.903 (0.868, 0.938) 0.019) H ssm 45.6 (38.0, 53.1) 39.1 (31.6, 46.7) 5.3 (0.0, 10.7) -1.1 (-6.5, 4.2) ism 38.4 (30.3, 46.5) 29.0 (20.8, 37.1) 6.8 (0, 13.9) -2.7 (-9.7, 4.4) ductivity loss 53.8 (45.1, 62.4) 42.4 (33.8, 51.0) 8.6 (0.9, 16.2) -2.8 (-10.4, 4.9) mpairment	Score Change from Baselin LSE (95% CI) LSE (95% CI) P-valueb Lalogue scale (VAS) -11.1 (-14.1, -8.2) <0.001 85.0 (82.1, 87.9) -2.3 (-5.2, 0.6) 0.119 dex (US weight) 0.842 (0.805, 0.879) -0.077 (-0.115, -0.040) 0.903 (0.868, 0.938) -0.016 (-0.051, 0.369 0.019) H sm	Change from Baseline LSE (95% CI) P- value ESw value ESw Value ESw Value ESw Value ESw Value ESw Value Value Value ESw Value Value	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{ c c c c c c c } \hline Score & Change from Baseline & Score & Change from LSE (95\% CI) & LSE (95\% CI) & P- & ES_w^c & LSE (95\% CI) & LSE (95$	$ \begin{array}{ c c c c c c c c } \hline Score & Change from Baseline & Page from Baseline & Score & Change from Baseline & Score & Change from Baseline & Page from Score & Change from Page from P$	$ \begin{array}{ c c c c c c c c } \hline Score & Change from Baseline & Score & Change from Baseline \\ LSE (95\% CI) & LSE (95\% CI) & P_{value}^{b} & ES_{w}^{c} & LSE (95\% CI) & LSE (95\% CI) & P_{value}^{b} & ES_{w}^{c} \\ \hline LSE (95\% CI) & LSE (95\% CI) & P_{value}^{b} & ES_{w}^{c} \\ \hline \hline Alogue scale (VAS) & & & & & & \\ \hline 76.2 (73.3, 79.2) & -11.1 (-14.1, -8.2) & -11.1 (-14.1, -8.2) & -11.9 & -14.8 (-17.6, -11.9) & -14.8 (-17.6$	Score Change from Baseline Score Change from Baseline LSE (95% CI) LSE (95% CI) LSE (95% CI) P- value Color LSE (95% CI) P- value Color Col	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$

Week 4	11.0 (5.1, 16.9)	-3.9 (-9.7, 2.0)	0.194	-0.15	21.3 (15.7, 26.9)	6.4 (0.8, 12.0)	0.025	0.19	-10.3 (-15.6, -5.0)	< 0.001	-0.34	
--------	------------------	------------------	-------	-------	----------------------	-----------------	-------	------	---------------------	---------	-------	--

Abbreviations: LSE = Least-Square Mean Estimate; CI = Confidence Interval.

- a Multivariate models include variables for time, vaccination status and interaction of time by vaccination status, as well as covariates
 of participant pre-COVID-19 symptom onset score, sociodemographic characteristics (age, sex, regions, social vulnerability,
 race/ethnicity, high risk occupations), previously tested positive for COVID-19, severity of acute illness (number of symptoms
 reported on index date), and immunocompromised status. Parameter estimates are presented in Supplemental Table 3.
- b P-value refers to the comparison of lease-square mean estimates score changes from baseline and 0 within BNT162b2 or Unvaccinated cohorts
- ^c ES_w, within-cohort effect size, was calculated as the least square estimate of mean change from divided by the observed standard deviation of change scores from baseline to follow-up.
 - ^d ES_b, between-cohort effect size, was calculated as the difference in least square estimates of mean changes from baseline between cohorts, divided by the observed pooled standard deviation of change scores
- ^eP-value refers to the difference in lease-square mean estimates between BNT162b2 and Unvaccinated cohorts.
- f Lower limit of 95% CI was truncated from -2.7 to 0 for absenteeism and -0.3 to 0 for presenteeism at Week 4 because the valid range is 0 to 100.



Mean dimension scores range from 1 for no problem to 5 for extreme / unable. The blue and red solid lines indicate that vaccinated and unvaccinated were similar at the pre-COVID baseline. At Day 3 and Week 4 post-index date, vaccinated cohort was less impacted (lower scores) than unvaccinated by COVID on anxiety/depression, pain/discomfort, and usual activities (dotted lines for Day 3, dashed lines for Week 4).

Supplemental Table 1 Patient Characteristics by Enrollment Status

Patient characteristics	Enrolled N=676	Not-Enrolled N=39,213	P value
Vaccinated			< 0.001
Yes	465 (68.8%)	22,125 (56.4%)	
No	211 (31.2%)	17,087 (43.6%)	
Missing			
Age, years			
Mean, SD	43.2 (14.7)	42.1 (15.5)	0.076
Median, Q1, Q3	41 (3155)	40 (2954)	0.010
Age Category			
18-29	134 (19.8%)	10,095 (25.7%)	0.005
30-49	317 (46.9%)	16,706 (42.6%)	
50-64	156 (23.1%)	8,561 (21.8%)	
≥65	69 (10.2%)	3,850 (9.8%)	
Gender, n (%)			< 0.001
Male	181 (26.8%)	17,843 (45.5%)	
Female	495 (73.2%)	21,370 (54.5%)	
Race / Ethnicity, n (%)			< 0.001
White or Caucasian (non-Hispanic or Latino)	486 (71.9%)	22,647 (57.8%)	
Black or African American	32 (4.7%)	4,162 (10.6%)	
Hispanic or Latino	85 (12.6%)	6,878 (17.5%)	
Asian	35 (5.2%)	2,551 (6.5%)	
Patient Refused	16 (2.4%)	1,535 (3.9%)	
Other	22 (3.3%)	1,439 (3.7%)	
US Geographic Region			0.258
Northeast	92 (13.6%)	4,387 (11.2%)	
South	402 (59.5%)	24,305 (62.0%)	
Midwest	118 (17.5%)	6,414 (16.4%)	
West	64 (9.5%)	4,105 (10.5%)	
Number of acute COVID-19 symptoms, Mean (SD)	5.2 (2.5)	5.1 (2.5)	0.732
Number of comorbidities, Mean (SD)	0.3 (0.7)	0.3 (0.6)	0.021
≥1 comorbidity	164 (24.3%)	7,677 (19.6%)	0.002

Supplemental Table 2 Summary of EQ-5D-5L Dimensions

Dimension	All	BNT162b2	Unvaccinated	P-value ^a
Pre-COVID-19 Baseline				
Mobility				0.841
No problems	396 (92.1%)	213 (91.4%)	183 (92.9%)	
Slight problems	30 (7.0%)	18 (7.7%)	12 (6.1%)	
Moderate problems	4 (0.9%)	2 (0.9%)	2 (1.0%)	
Severe problems	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Self-Care				0.560
No problems	419 (97.4%)	226 (97.0%)	193 (98.0%)	
Slight problems	11 (2.6%)	7 (3.0%)	4 (2.0%)	
Moderate problems	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Severe problems	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Usual Activities				0.904
No problems	394 (91.6%)	214 (91.8%)	180 (91.4%)	
Slight problems	23 (5.4%)	11 (4.7%)	12 (6.1%)	
Moderate problems	12 (2.8%)	7 (3.0%)	5 (2.5%)	
Severe problems	1 (0.2%)	1 (0.4%)	0 (0.0%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Pain / Discomfort				0.614
No	307 (71.4%)	172 (73.8%)	135 (68.5%)	
Slight	93 (21.6%)	46 (19.7%)	47 (23.9%)	
Moderate	27 (6.3%)	13 (5.6%)	14 (7.1%)	
Severe	3 (0.7%)	2 (0.9%)	1 (0.5%)	
Extreme	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Anxiety / Depression				0.395
No	230 (53.5%)	124 (53.2%)	106 (53.8%)	
Slightly	140 (32.6%)	80 (34.3%)	60 (30.5%)	
Moderately	49 (11.4%)	26 (11.2%)	23 (11.7%)	
Severely	10 (2.3%)	3 (1.3%)	7 (3.6%)	
Extremely	1 (0.2%)	0 (0.0%)	1 (0.5%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Days 3				
Mobility				0.131

No muchlance	242 (70.90/)	102 (92 90/)	150 (76 10/)	1
No problems	343 (79.8%)	193 (82.8%)	150 (76.1%)	
Slight problems	68 (15.8%)	31 (13.3%)	37 (18.8%)	
Moderate problems	17 (4.0%)	7 (3.0%)	10 (5.1%)	
Severe problems	2 (0.5%)	2 (0.9%)	0 (0.0%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Self-Care				0.571
No problems	370 (86.0%)	205 (88.0%)	165 (83.8%)	
Slight problems	47 (10.9%)	21 (9.0%)	26 (13.2%)	
Moderate problems	11 (2.6%)	6 (2.6%)	5 (2.5%)	
Severe problems	2 (0.5%)	1 (0.4%)	1 (0.5%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Usual Activities				0.361
No problems	207 (48.1%)	117 (50.2%)	90 (45.7%)	
Slight problems	132 (30.7%)	75 (32.2%)	57 (28.9%)	
Moderate problems	64 (14.9%)	30 (12.9%)	34 (17.3%)	
Severe problems	21 (4.9%)	9 (3.9%)	12 (6.1%)	
Unable	6 (1.4%)	2 (0.9%)	4 (2.0%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Pain / Discomfort		,	,	0.080
No	145 (33.7%)	85 (36.5%)	60 (30.5%)	
Slight	183 (42.6%)	99 (42.5%)	84 (42.6%)	
Moderate	82 (19.1%)	43 (18.5%)	39 (19.8%)	
Severe	17 (4.0%)	4 (1.7%)	13 (6.6%)	
Extreme	3 (0.7%)	2 (0.9%)	1 (0.5%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Anxiety / Depression		, ,	,	0.047
No	190 (44.2%)	108 (46.4%)	82 (41.6%)	
Slightly	135 (31.4%)	79 (33.9%)	56 (28.4%)	
Moderately	75 (17.4%)	37 (15.9%)	38 (19.3%)	
Severely	26 (6.1%)	8 (3.4%)	18 (9.1%)	
Extremely	4 (0.9%)	1 (0.4%)	3 (1.5%)	
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Week 4	(3.07.0)	(3.073)	(0.070)	
Mobility				0.278
No problems	270 (81.3%)	149 (84.7%)	121 (77.6%)	1 - 7 - 7
Slight problems	49 (14.8%)	22 (12.5%)	27 (17.3%)	
Moderate problems	12 (3.6%)	5 (2.8%)	7 (4.5%)	
Severe problems	1 (0.3%)	0 (0.0%)	1 (0.6%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Onable	0 (0.070)	0 (0.070)	0 (0.070)	

Missing	1 (0.0%)	1 (0.0%)	0 (0.0%)	
Self-Care				0.068
No problems	308 (93.1%)	167 (94.9%)	141 (91.0%)	
Slight problems	17 (5.1%)	5 (2.8%)	12 (7.7%)	
Moderate problems	5 (1.5%)	4 (2.3%)	1 (0.7%)	
Severe problems	1 (0.3%)	0 (0.0%)	1 (0.7%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	2 (0.0%)	1 (0.0%)	1 (0.0%)	
Usual Activities				0.152
No problems	232 (70.1%)	132 (75.0%)	100 (64.5%)	
Slight problems	75 (22.7%)	35 (19.9%)	40 (25.8%)	
Moderate problems	20 (6.0%)	8 (4.6%)	12 (7.7%)	
Severe problems	4 (1.2%)	1 (0.6%)	3 (1.9%)	
Unable	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Missing	2 (0.0%)	1 (0.0%)	1 (0.0%)	
Pain / Discomfort				0.097
No	170 (51.4%)	95 (54.0%)	75 (48.4%)	
Slight	118 (35.6%)	66 (37.5%)	52 (33.5%)	
Moderate	37 (11.2%)	13 (7.4%)	24 (15.5%)	
Severe	5 (1.5%)	2 (1.1%)	3 (1.9%)	
Extreme	1 (0.3%)	0 (0.0%)	1 (0.7%)	
Missing	2 (0.0%)	1 (0.0%)	1 (0.0%)	
Anxiety / Depression				0.605
No	167 (50.5%)	92 (52.3%)	75 (48.4%)	
Slightly	98 (29.6%)	53 (30.1%)	45 (29.0%)	
Moderately	51 (15.4%)	25 (14.2%)	26 (16.8%)	
Severely	10 (3.0%)	5 (2.8%)	5 (3.2%)	
Extremely	5 (1.5%)	1 (0.6%)	4 (2.6%)	
Missing	2 (0.0%)	1 (0.0%)	1 (0.0%)	


 $^{^{\}rm a}$ P values of Freeman-Halton tests comparing BNT162b2 cohort and unvaccinated cohort, excluding category of missing.

Supplemental Table 3 Mixed Models for Repeated Measurements EQ-5D-5L and WPAI-GH Scores


	EQ VA	AS	EQ-5D-5L Util (U.S. weig	•	Absente	eism	Presente	eeism	Work prod		Activity imp	pairment
	Coeff (SE)	P value	Coeff (SE)	P value	Coeff (SE)	P value	Coeff (SE)	P value	Coeff (SE)	P value	Coeff (SE)	P value
Intercept	4.51 (5.36)	0.401	0.038 (0.062)	0.546	53.6 (4.9)	< 0.001	41.4 (5.7)	< 0.001	57.7 (6.0)	< 0.001	41.2 (4.9)	< 0.001
Vaccinated												
BNT162B2BNT162b2	3.65 (1.46)	0.013	0.069 (0.019)	< 0.001	-19.4 (4.5)	< 0.001	-8.4 (4.2)	0.047	-11.2 (4.4)	0.012	-6.3 (3.1)	0.044
No	Reference		Reference		Reference		Reference		Reference		Reference	
Assessment Time												
Day 2-4 / Week 1	Reference		Reference		Reference		Reference		Reference		Reference	
Week 4	9.04 (1.23)	< 0.001	0.086 (0.014)	< 0.001	-62.9 (3.4)	< 0.001	-30.9 (3.3)	< 0.001	-48.0 (3.6)	< 0.001	-28.9 (2.5)	< 0.001
Assessment Time * Vacc	inated											
Day 2-4 / Week 1 * BNT162b2	Reference		Reference		Reference		Reference		Reference		Reference	
Week 4 * BNT162B2	-0.25 (1.69)	0.884	-0.025 (0.020)	0.209	22.6 (4.8)	< 0.001	-0.8 (4.4)	0.863	2.8 (4.8)	0.561	-4.0 (3.5)	0.257
Pre-COVID-19 Baseline Score	-0.22 (0.05)	< 0.001	-0.177 (0.057)	0.002	-0.8 (0.0)	< 0.001	-0.7 (0.1)	< 0.001	-0.8 (0.1)	<0.001	-0.7 (0.0)	<0.001
Age, years												
18-29	Reference		Reference		Reference		Reference		Reference		Reference	
30-49	-1.82 (1.45)	0.211	-0.011 (0.018)	0.532	3.9 (2.4)	0.102	5.6 (3.0)	0.065	4.1 (3.2)	0.204	7.8 (2.9)	0.006
50-64	-2.84 (1.74)	0.102	-0.048 (0.021)	0.025	10.8 (2.9)	< 0.001	6.8 (3.8)	0.074	7.3 (4.1)	0.075	13.7 (3.5)	< 0.001
≥65	-1.86 (2.29)	0.417	-0.025 (0.028)	0.367	1.7 (5.5)	0.760	0.3 (7.4)	0.964	-1.4 (7.9)	0.863	6.9 (4.7)	0.139
Gender												
Male	4.07 (1.30)	0.002	0.028 (0.016)	0.080	-2.1 (2.2)	0.360	-6.8 (2.9)	0.019	-5.8 (3.1)	0.057	-9.8 (2.6)	< 0.001
Female	Reference		Reference		Reference		Reference		Reference		Reference	
Race / Ethnicity												
White (non-Hispanic)	Reference		Reference		Reference		Reference		Reference	_	Reference	
Black/African American	2.17 (2.73)	0.428	0.017 (0.033)	0.613	-1.8 (5.1)	0.726	0.8 (6.4)	0.899	0.1 (7.1)	0.994	-1.9 (5.6)	0.730
Hispanic or Latino	0.65 (1.68)	0.701	0.005 (0.021)	0.818	-1.9 (3.0)	0.530	4.3 (3.9)	0.268	4.8 (4.1)	0.243	-2.3 (3.4)	0.494

Asian	4.24 (2.54)	0.096	0.032 (0.031)	0.316	-1.7 (4.7)	0.713	1.4 (5.8)	0.807	2.4 (6.3)	0.705	0.9 (5.2)	0.858
Patient refused	-0.30 (3.26)	0.927	0.031 (0.040)	0.438	-3.3 (6.1)	0.589	1.1 (8.4)	0.897	-2.3 (9.0)	0.800	-6.4 (7.0)	0.359
Other	2.90 (2.81)	0.303	0.019 (0.035)	0.582	3.9 (4.8)	0.418	-6.9 (6.5)	0.288	-3.1 (6.9)	0.661	-7.5 (5.8)	0.198
Region												
Northeast	1.91 (2.00)	0.341	0.015 (0.025)	0.534	6.2 (3.3)	0.057	-1.9 (4.2)	0.648	-0.5 (4.5)	0.908	-2.3 (3.9)	0.551
South	0.87 (1.51)	0.568	-0.002 (0.019)	0.905	-1.0 (2.6)	0.698	-2.4 (3.3)	0.466	-2.4 (3.5)	0.507	-2.9 (3.0)	0.328
Midwest	Reference		Reference		Reference		Reference		Reference		Reference	
West	0.49 (2.08)	0.815	0.019 (0.026)	0.448	-0.7 (3.4)	0.830	-0.8 (4.5)	0.857	-1.3 (4.8)	0.793	-3.7 (4.2)	0.374
Social Vulnerability Index												
<0.25	Reference		Reference		Reference		Reference		Reference		Reference	
≥0.25 and <0.5	1.21 (1.45)	0.403	0.034 (0.018)	0.060	1.3 (2.4)	0.579	-3.9 (3.0)	0.196	-4.6 (3.3)	0.158	-5.2 (2.9)	0.076
≥0.5 and <0.75	0.93 (1.62)	0.568	0.020 (0.020)	0.321	4.7 (2.8)	0.090	-4.8 (3.6)	0.180	-6.0 (3.9)	0.124	-3.6 (3.3)	0.276
≥0.75	-2.80 (2.14)	0.192	0.009 (0.026)	0.740	2.3 (3.7)	0.531	-9.3 (4.7)	0.048	-7.8 (5.0)	0.121	-5.0 (4.3)	0.247
Previously tested positive	0.99 (1.13)	0.381	0.003 (0.014)	0.816	-1.9 (2.0)	0.333	-0.5 (2.6)	0.851	-2.7 (2.8)	0.329	-1.2 (2.3)	0.591
Work in healthcare	-0.90 (1.80)	0.616	-0.018 (0.022)	0.424	3.1 (2.8)	0.272	0.8 (3.6)	0.818	-0.7 (4.0)	0.851	3.7 (3.6)	0.300
Work in high-risk setting	-2.83 (1.96)	0.150	-0.006 (0.024)	0.790	4.7 (3.4)	0.166	10.3 (4.3)	0.017	13.3 (4.6)	0.004	5.7 (4.0)	0.155
Live in high-risk setting	1.36 (2.53)	0.591	-0.028 (0.031)	0.370	3.2 (4.7)	0.502	4.8 (6.0)	0.431	7.2 (6.5)	0.268	12.1 (5.0)	0.017
Immunocompromised	1.22 (2.61)	0.639	-0.018 (0.032)	0.560	13.1 (6.1)	0.033	9.9 (8.4)	0.243	7.9 (9.1)	0.385	5.5 (5.1)	0.282
Number of Symptoms on index day	-0.59 (0.23)	0.009	-0.010 (0.003)	0.001	0.8 (0.4)	0.048	1.3 (0.5)	0.008	1.9 (0.5)	0.001	1.8 (0.4)	<0.001

Supplemental Figure 1 Least-Square Estimates and 95% Confidence Intervals of EQ-5D-5L Scores ^a




^a Score ranges: EQ-5D-5L VAS 0 to 100, EQ-5D-5L UI (the United States weights) -0.573 to 1.




^a Score ranges: EQ-5D-5L VAS 0 to 100, EQ-5D-5L UI (the United States weights) -0.573 to 1. Dots are the mean values and whiskers are the 95% Confidence Intervals. The Pre-COVID values represent the pooled means with 95% Confidence Internals. The Day 3 and Week 4 values are the least square estimate scores.

Supplemental Figure 3 Least-Square Estimates and 95% Confidence Intervals of WPAI-GH Scores ^a



^a WPAI-GH score (absenteeism, presenteeism, work productivity loss, and activity impairment) ranges from 0 to 100 percent.



WPAI-GH score (absenteeism, presenteeism, work productivity loss, and activity impairment) ranges from 0 to 100 percent. Dots are the mean values and whiskers are the 95% Confidence Intervals. The Pre-COVID values represent the pooled means with 95% Confidence Internals. The Week 1 and Week 4 values are the least square estimate scores.

Supplemental Table 4 Model Predicting the Missingness at Week 1 and Week 4

	S	ummary: % (n) / M	ean (SD)	Model			
	Total	Week 1 Missing	Week 4 Missing	Coeff (SE)	P value	Odds Ratio	
Intercept	430	11.9% (51)	23.0% (99)	-3.14 (1.19)	0.009		
Assessment Time		ì	, ,				
Week 4	430		23.0% (99)	0.85 (0.12)	< 0.001	2.3 (1.9, 2.9)	
Week 1	430	11.9% (51)		Reference		1.0	
Vaccination status		ì					
BNT162b2	233	12.9% (30)	24.5% (57)	0.36 (0.26)	0.166	1.4 (0.9, 2.4)	
Unvaccinated	197	10.7% (21)	21.3% (42)	Reference	•	1.0	
EQ VAS on Day 3	72.9		, ,	0.00 (0.01)	0.967	1.0 (1.0, 1.0)	
	(17.5)	68.9 (19.1)	71.7 (17.3)				
EQ VAS change from pre-	-14.4	-18.2 (18.9)	-16.0 (16.6)	-0.01 (0.01)	0.311	1.0 (1.0, 1.0)	
COVID-19 baseline to Day 3	(14.8)						
Age, years							
18-29	87	8.0% (7)	16.1% (14)	Reference	•	1.0	
30-49	213	10.3% (22)	23.9% (51)	0.69 (0.36)	0.052	2.0 (1.0, 4.0)	
50-64	94	16.0% (15)	27.7% (26)	0.94 (0.40)	0.019	2.6 (1.2, 5.6)	
≥65	36	19.4% (7)	22.2% (8)	0.72 (0.52)	0.161	2.1 (0.8, 5.6)	
Gender							
Male	103	4.9% (5)	16.5% (17)	-0.80 (0.32)	0.013	0.4 (0.2, 0.8)	
Female	327	14.1% (46)	25.1% (82)	Reference		1.0	
Race / Ethnicity			, ,				
White (non-Hispanic)	295	9.8% (29)	19.7% (58)	Reference	•	1.0	
Black/African American	20	20.0% (4)	35.0% (7)	0.67 (0.50)	0.184	2.0 (0.7, 5.3)	
Hispanic or Latino	61	11.5% (7)	27.9% (17)	0.21 (0.36)	0.565	1.2 (0.6, 2.5)	
Asian	22	18.2% (4)	27.3% (6)	0.37 (0.52)	0.480	1.4 (0.5, 4.0)	

Patient refused	13	30.8% (4)	30.8% (4)	0.94 (0.62)	0.128	2.6 (0.8, 8.6)
Other	19	15.8% (3)	36.8% (7)	1.22 (0.54)	0.024	3.4 (1.2, 9.8)
Region						
Northeast	52	7.7% (4)	21.2% (11)	0.50 (0.48)	0.295	1.7 (0.6, 4.2)
South	252	13.5% (34)	24.6% (62)	0.32 (0.37)	0.378	1.4 (0.7, 2.8)
Midwest	77	6.5% (5)	16.9% (13)	Reference		1.0
West	49	16.3% (8)	26.5% (13)	0.44 (0.47)	0.343	1.6 (0.6, 3.9)
Social Vulnerability Index						
<0.25	98	12.2% (12)	22.4% (22)	Reference		1.0
≥0.25 and <0.5	164	9.8% (16)	19.5% (32)	-0.22 (0.33)	0.496	0.8 (0.4, 1.5)
≥0.5 and <0.75	120	12.5% (15)	25.0% (30)	0.07 (0.35)	0.850	1.1 (0.5, 2.1)
≥0.75	48	16.7% (8)	31.3% (15)	0.38 (0.45)	0.397	1.5 (0.6, 3.5)
Previously tested positive	167	15.6% (26)	26.9% (45)	0.45 (0.25)	0.069	1.6 (1.0, 2.5)
Work in healthcare	47	12.8% (6)	19.1% (9)	-0.24 (0.42)	0.567	0.8 (0.3, 1.8)
Work in high-risk setting	44	13.6% (6)	22.7% (10)	-0.25 (0.43)	0.559	0.8 (0.3, 1.8)
Live in high-risk setting	22	9.1% (2)	27.3% (6)	0.38 (0.54)	0.484	1.5 (0.5, 4.3)
Immunocompromised	19	10.5% (2)	15.8% (3)	-0.33 (0.67)	0.623	0.7 (0.2, 2.7)
Number of Symptoms on index						
day	5.3 (2.6)	5.4 (2.6)	5.0 (2.5)	-0.07 (0.05)	0.188	0.9 (0.8, 1.0)